* Lipocine Inc LPCN.OQ LPCN.O is expected to show no
change in
quarterly revenue when it reports results on March 8
(estimated) for the period ending December 31 2023
*
* LSEG's mean analyst estimate for Lipocine Inc is for a
loss
of 47 cents per share.
* The one available analyst rating on the shares is "strong
buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Lipocine
Inc is
$33.00, above its last closing price of $3.64.
This summary was machine generated March 6 at 13:41 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)